Logo

QNTM

Quantum BioPharma Ltd.

QNTM

Quantum BioPharma Ltd. • NASDAQ
$9.70 ▼ -14.99% (-1.71)
Market Cap $37.02 M
52w High $38.25
52w Low $2.70
Dividend Yield 0%
P/E -1.02
Volume 660.50K
Outstanding Shares 3.82M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.748M ▼ $-5.319M ▲ 0% $-1.25 ▲ $-4.497M ▲
Q2-2025 $0 $4.853M ▲ $-9.253M ▼ 0% $-3.23 ▲ $-9.389M ▼
Q1-2025 $0 $3.397M ▼ $-8.577M ▼ 0% $-7.52 ▼ $-8.26M ▼
Q4-2024 $0 $6.241M ▲ $-5.36M ▼ 0% $-5.22 ▼ $-5.327M ▼
Q3-2024 $0 $4.181M $-3.827M 0% $-4.17 $-3.884M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.083M ▼ $14.153M ▼ $6.646M ▼ $8.652M ▲
Q2-2025 $1.528M ▼ $15.297M ▲ $13.25M ▲ $3.764M ▼
Q1-2025 $3.539M ▼ $14.873M ▼ $10.344M ▲ $5.733M ▼
Q4-2024 $7.198M ▲ $17.119M ▼ $6.679M ▲ $11.481M ▼
Q3-2024 $6.606M $19.027M $3.681M $16.29M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.748M ▲ $-1.721M ▲ $408.419K ▲ $261.425K ▼ $-1.052M ▲ $-1.721M ▲
Q2-2025 $-9.766M ▼ $-1.949M ▲ $-1.361M ▼ $1.29M ▼ $-2.021M ▲ $-1.949M ▲
Q1-2025 $-8.74M ▼ $-4.261M ▼ $-1.35M ▼ $3.133M ▲ $-2.478M ▼ $-4.261M ▼
Q4-2024 $-5.456M ▼ $-835.762K ▲ $1.244M ▲ $2.468M ▼ $2.876M ▲ $-835.762K ▲
Q3-2024 $-4.015M $-3.461M $-3.464M $6.738M $-186.415K $-3.461M

Five-Year Company Overview

Income Statement

Income Statement Quantum BioPharma is still a classic early‑stage biotech story: there is essentially no product revenue yet, and the business runs at a steady operating loss each year. Losses have been relatively small in absolute size and have narrowed slightly over time, but the company is still firmly in the spending phase, not the earning phase. The cost base appears lean, which is typical for a small R&D‑focused company with a limited commercial footprint, but profitability will likely depend entirely on the success and timing of its drug candidates and other ventures.

Balance Sheet

Balance Sheet The balance sheet is very light, reflecting a small company with modest assets and limited cash on hand. On the positive side, there is no financial debt reported, which reduces pressure from interest payments and refinancing risk. Equity is positive but thin, giving the company only a modest cushion to absorb ongoing losses. Overall, the financial position appears clean but fragile: simple capital structure, no leverage, yet not a lot of room for long delays or setbacks without seeking fresh external funding or monetizing investments.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, which is expected for a development‑stage biotech with no revenue. The company does not appear to be spending heavily on physical assets, so most cash burn is tied to operating expenses and R&D rather than large capital projects. This keeps the cost structure flexible but means continued progress relies on access to outside capital or cash inflows from its strategic investment activities or consumer wellness initiatives. At current scale, cash management and timing of financing will remain critical.

Competitive Edge

Competitive Edge Quantum BioPharma’s competitive position rests on a few differentiated pillars rather than size or market share. Its lead MS candidate aims to repair nerve damage without suppressing the immune system, which, if proven in humans, would be a meaningful distinction versus many existing treatments. The company also stands out by mixing traditional drug development with secured lending and a consumer wellness brand, which could provide more diversified income sources than a typical single‑asset biotech. Partnerships around quantum computing and an experienced leadership team add credibility, but the firm still competes against much larger, better‑funded pharmaceutical players. Until late‑stage clinical data arrive and products gain meaningful traction, its competitive moat will remain more potential than proven.

Innovation and R&D

Innovation and R&D Innovation is the core of Quantum BioPharma’s story. The Lucid‑MS program targets multiple sclerosis with a novel, non‑immunosuppressive approach and has already cleared early human safety milestones, with efforts underway to move into more advanced trials and fast‑track regulatory pathways. Additional programs, like its anti‑inflammatory candidate and depression‑focused compound, provide some pipeline breadth beyond a single bet. The company is also experimenting with quantum computing to speed up drug discovery, an ambitious but still largely unproven edge. On top of that, the Unbuzzd wellness product introduces a different kind of innovation aimed at the consumer market. The upside from this R&D portfolio could be significant, but success depends heavily on future trial results and regulatory outcomes, which are inherently uncertain.

Summary

Quantum BioPharma is a very early‑stage, pre‑revenue biotech with a slim but clean balance sheet, steady cash burn, and no financial debt. The investment case centers almost entirely on future prospects: a potentially first‑in‑class MS therapy, additional drug candidates, quantum‑enabled discovery ambitions, and a consumer wellness brand plus secured lending arm that make its business model more diversified than usual for a company of its size. The flip side is that scale is tiny, financial resources are limited, and everything depends on successful execution in clinical trials, commercialization, and legal matters, including a large ongoing lawsuit. Overall, this is a high‑uncertainty, innovation‑driven story where the scientific and commercial outcomes will likely matter far more than recent historical financials.

NEWS

November 27, 2025 · 4:00 PM UTC

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Read more

November 26, 2025 · 9:30 AM UTC

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Read more

November 25, 2025 · 4:00 PM UTC

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Read more

November 7, 2025 · 7:00 AM UTC

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Read more

October 31, 2025 · 7:51 PM UTC

Quantum BioPharma Ltd. Provides Corporate Update

Read more